MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies

MindWalk Holdings (NASDAQ: HYFT) announced three senior scientific appointments as its pipeline advances toward preclinical efficacy studies. Zachary Maben (Arbor Biotechnologies, ex-Pfizer) joins as Director of Antigen Discovery & Protein Engineering, and Joanne Lim (Orum Therapeutics, ex-Codiak and Novartis) joins as Director of Preclinical Development; internal VP Shuji Sato expands his role to include the pipeline. The hires build out Boston-based preclinical and structural biology capability ahead of efficacy studies, with management framing the moves as deepening portfolio decision-making as preclinical data emerge.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.